Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bowel Dysfunction After Rectal Cancer Treatment

ABSTRACT: Bowel dysfunction after rectal cancer treatment may significantly affect the quality of life. Our study aimed to estimate the incidence and characterize the Low Anterior Resection Syndrome(LARS). We performed a prospective evaluation of patients treated with anterior resection for rectal cancer at two hospitals. Assessment was performed at baseline, after neoadjuvant treatment, and 1, 6 and 12 months after bowel transit reconstruction using the following scores: Bristol scale, LARS score, MSK-BFI, FIQL, EORTC-QLQ30 and a visual analogue scale.

DISEASE(S): Intestinal Diseases,Low Anterior Resection Syndrome

PROVIDER: 2387782 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Bowel Dysfunction 3 Years After Anterior Resection a in a Swedish National Cohort

Project description:The primary objectives are to evaluate the prevalence of LARS and Quality of Life in rectal cancer patients 3 years after anterior resection, to investigate if anastomotic technique is a risk factor for major LARS and to study the prevalence of colostomy 3 years after anterior resection and evaluate stoma function according to the stoma scale in EORTC QLQ-CR29.

| 2354860 | ecrin-mdr-crc

Long - Term Low Anterior Resection Syndrome

Project description:Data assessing the long-term bowel dysfunction following low anterior resection is still lacking. The aim of this study is to evaluate late functional results of patients who underwent rectal resection for rectal cancer. This included calculating LARS and Wexner score and identifying possible risk factors of late postoperative bowel disorders.

| 2303269 | ecrin-mdr-crc

Study of the changes in bowel movements after surgery for rectal cancer and how it affects the quality of life of such patients.

Project description:Intervention1: LARS score: All patients who undergo had undergone low anterior resection for rectal cancer in Regional Cancer, one year before will be interviewed by a trained interviewer twice at 3-6 months interval using Wexner Incontinence Score 2.LARS Malayalam Questionnaire 3.EORTC QLQ C30 and CR 29 Malayalam translations for measuring QOL. Primary outcome(s): Incidence of LARS syndrome in patients undergoing low anterior resection for rectal cancer.Timepoint: Post surgery, 3 months and 6 months post op.

| 2595345 | ecrin-mdr-crc

Evaluation of short- und long-term morbidity of bowel mobilisation in patients with epithelial ovarian cancer after primary undergoing debulking surgery with special interest on Low anterior resection syndrome (LARS) - a retrospective analysis.

Project description:Interventions: Group 1: Evaluation of the LARS score in patients undergoing debulking surgery for ovarian cancer who underwent sigma / rectosigmoid or deep anterior rectal resection. The control cohort will be: 1) Ovarian cancer patients who underwent debulking surgery without sigma/rectum resection; 2) breast cancer patients (matched-pair) who have neo / adjuvant chemotherapy based on their diagnosis but no history of abdominal/bowel surgery. Primary outcome(s): The aim of the present study is to evaluate the prevalence of the low anterior resection syndrome (LARS) in patients with advanced epithelial ovarian cancer.. Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other

| 2435021 | ecrin-mdr-crc

stool samples from patients with low anterior resection syndrome after rectal cancer surgery

Project description:Gut Microbiome Associated with Low Anterior Resection Syndrome after Rectal Cancer Surgery

| PRJNA882613 | ENA

Charged tRNA profiling of mcf10a, HCC1806 cells, polysome profiling, RNA-Seq and Ribo-Seq in 4T07 cells upon LARS knockdown by shRNA, and RNA-Seq of ribosome-associated RNAs in Lars depleted PyMT tumors

Project description:In this study, we identify leucyl-tRNA synthetase (LARS) as a breast tumor suppressor. To identify the mechanism underlying LARS-mediated breast tumor suppression, we first conducted charged tRNA profiling to assess charged and total tRNA-Leu expression in cell lines with high and low LARS expression. Expression of select charged and total tRNA-Leu isoacceptors were reduced in cell lines with lower LARS expression. We then conducted RNA-Seq and translation profiling including ribosome profiling (Ribo-Seq), polysome profiling in LARS-depleted cell lines. To test our hypothesis in vivo, we also performed RNA-Seq of ribosome-associated RNAs in Lars depleted PyMT tumors within RiboTag mice. The analyses implicate LARS as a regulator of leucine-rich translation.

2022-01-05 | GSE176130 | GEO

Translation of the International Consensus Definition of LARS Into a Bowl Dysfunction Severity Scoring Tool (New LARS Score)

Project description:The purpose of this study is to develop a new severity scoring tool for Low Anterior Resection Syndrome (LARS) drawing on the international consensus criteria for LARS as well as opinions of patients with lived-experience of LARS.

| 2753375 | ecrin-mdr-crc

Role of Diet and Faecal Microbiota Transplantation following Bowel Cancer Surgery

Project description:Interventions: Following bowel resection due to cancer, up to 80% patients will experience variable and unpredictable bowel function and symptoms termed as Low Anterior Resection Syndrome (LARS). The exact mechanism of LARS remains unclear and currently there is no standard treatment. This program of research will investigate if Faecal Microbiota Transplantation (FMT) can improve the bowel function and patient’s quality of life (QoL). Phase 1- Dose-finding-study. Group 1: FMT at one year post Ultra Low Anterior Resection (ULAR)/LAR via lower route (colonoscopy). Dose includes 4 x BiomeBoostTM FMT syringes, containing a total of 50 g of faecal matter as the active ingredient. Group 2: FMT at one year post ULAR/LAR via lower route (colonoscopy). Dose includes 6 x BiomeBoostTM FMT syringes, containing a total of 75 g of faecal matter as the active ingredient. FMT dose will be administered at one time, by the specialist conducting the colonoscopy (gastroenterologist/surgeon). The procedure of delivering FMT will only add 5 minutes to the routine colonoscopy being performed. Adherence will be monitored by: 1. Dietetic phone follow up How well did you follow the intervention in a non judgmental format. Primary outcome(s): Bowel function assessed via Low Anterior Resection Syndrome (LARS) questionnaire [At baseline (week 0) and week 4 post intervention commencement.];General quality of life (QoL) assessed via Cancer Quality of Life-general post cancer questionnaire (EORTC QLQ-C30) [At baseline (week 0) and week 4 post intervention commencement.];Colorectal specific quality of life (QoL) assessed via Colorectal specific QoL (EORTC QLQ-C30) questionnaire [At baseline (week 0) and week 4 post intervention commencement.] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy

| 2472786 | ecrin-mdr-crc

Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)

Project description:Bowel dysfunction is common after a restorative rectal cancer resection. Neoadjuvant radiotherapy is an influential factor that impairs bowel function and quality of life. However, almost half patients who have received primary surgery with preoperative radiotherapy are able to restore a good or moderate bowel function in the long term. This multicenter observational study aims to identify the risk factors of severe bowel dysfunction after rectal cancer resection and neoadjuvant radiotherapy, in accordance with the LARS score, and to build a model that predicts long-term major LARS in the early stage of follow-up. Development and validation cohorts are enrolled from tertiary hospitals in China.

| 2396173 | ecrin-mdr-crc

Postoperative Bowel Function After SPS by Different Reconstruction Methods

Project description:Colorectal cancer is one of the most common malignant tumors in the world. Surgery is still the main treatment for rectal cancer. With the popularization of stapler technology and the application of preoperative neoadjuvant therapy, more and more patients with rectal cancer have treated sphincter preservation surgery for rectal cancer. postoperative observation found that some patients with rectal cancer anus-preserving surgery had different degrees of defecation dysfunction after surgery, such as incontinence, tightness, increased frequency of bowel movements, and constipation. These clinical symptoms have been classified as "Low anterior resection syndrome (LARS)" in recent years.Now there is no treatment for LARS.Meanwhile,J-pouch and side-to-end anastomosis can help the patients,but there is few trials can prove this.This trial means to prove weather side-to-end anastomosis can improve bowel of rectal patients afer surgery.

| 2283992 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data